Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports
来源：Fierce Biotech | 发布时间：2026-04-30
摘要：Anthropic以4亿美元收购成立仅8个月的Coefficient Bio，将其“智能体工作区”技术整合进Claude for Life Sciences，推动AI从科研辅助工具升级为可自主执行药物研发全流程任务的“AI科学家”。此次收购是Anthropic深耕生命科学垂直领域的关键布局，通过技术融合与人才引入，构建覆盖“假设-实验-反馈”全链路的AI研发生态，目标成为全球生物学研究的底层操作系统。
AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI biotech startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric Newcomer.
TechCrunch also confirmed the acquisition through sources close to the deal, and Coefficient’s PitchBook page reflects the $400 million transaction as well. Anthropic and Coefficient have not yet responded to Fierce Biotech’s requests for confirmation.
According to Coefficient’s LinkedIn page, Aris Theologis is Coefficient’s CEO and co-founder. He previously served as chief business officer at Evozyne and as a vice president at Paragon Biosciences. He is also experienced in AI partnerships; his LinkedIn profile notes that he established and expanded a partnership with Nvidia during his time at Evozyne. According to PitchBook, New York-based Coefficient was founded in 2025 and had six employees.
Theologis is joined by co-founder and chief technology officer Nathan Frey, who was a principal scientist at Biogen until September of last year. A third co-founder, Joyce Hong, previously spent nearly five years as a principal at Roivant Sciences, according to LinkedIn.
Coefficient leverages AI in a bid to boost efficiency in drug discovery and biological research, according to TechCrunch.
Anthropic, for its part, has spent the past six months expanding its healthcare presence, launching Claude for Life Sciences in October and Claude for Healthcare in January. The company has also announced new capabilities in life sciences, spanning preclinical R&D through clinical operations and regulatory affairs.
Eric Kauderer-Abrams, head of biology and life sciences at Anthropic, told Fierce in January that healthcare and life sciences represent one of the company’s largest strategic bets. “For life sciences, it’s about making sure that our models have skills spanning everything from early-stage discovery through translation and commercialization, and that they connect to the tools that scientists and life science professionals are using every day,” he said.
4亿美元收购不到9人的AI公司，亚马逊等巨头试水新方向
近日，由亚马逊、谷歌等巨头投资的 Anthropic（ANTHRO），以高于4亿美元的价格收购了开发生物研究AI模型的生物技术公司Coefficient Bio。交易完成后，Coefficient Bio 将加入Anthropic医疗保健生命科学团队。
Coefficient Bio总部位于纽约，去年9月刚刚成立，创始人Samuel Stanton和Nathan C. Frey曾在基因泰克药物研发部门，从事计算药物研发工作。成立8个月以来，公司一直处于隐形状态，团队规模可能不会超过9个人，并且没有公开任何产品。据悉，基因疗法公司Dimension Therapeutics投资了Coefficient Bio，并持有半数股权。
Anthropic与Coefficient Bio达成的这笔交易，是Anthropic在医疗保健领域的最新尝试。去年10 月，该公司推出了用于生命科学领域的AI工具 Claude。就在几个月前，该公司聘请了业内资深人士Eric Kauderer-Abrams 担任其生物学和生命科学部门的负责人。
业内人士认为，这一收购显示了人工智能未来的发展方向——正在从“通用人工智能”的时代步入高价值垂直人工智能时代，行业目标已经从写邮件这类小事转向攻克生物学难